Experienced in Autoimmune Hemolytic Anemia

Dr. Jedd Wolchok

Hematology | Oncology
Weill Medical College Of Cornell
1305 York Ave, 
New York, NY 
Offers Telehealth
Experienced in Autoimmune Hemolytic Anemia
Weill Medical College Of Cornell
1305 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jedd Wolchok is a Hematologist and an Oncologist in New York, New York. Dr. Wolchok is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Melanoma, Neuroendocrine Tumor, Anal Cancer, Liver Embolization, and Bone Marrow Transplant.

His clinical research consists of co-authoring 412 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Autoimmune Hemolytic Anemia.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

WEILL MEDICAL COLLEGE OF CORNELL
1305 York Ave, New York, NY 10021

Additional Areas of Focus

Dr. Wolchok has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose
Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Phase: Phase 1
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Biological
Study Drug: MAB HER 2 (HERCEPTIN)
Study Phase: Phase 1
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase I Study of Positron Emission Tomography (PET/CT) With ⁸⁹Zr-Df-IAB22M2C in Patients With Selected Solid Malignancies (Non Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Squamous Cell Carcinoma Head and Neck (SqCCHN), Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma
A Phase I Study of Positron Emission Tomography (PET/CT) With ⁸⁹Zr-Df-IAB22M2C in Patients With Selected Solid Malignancies (Non Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Squamous Cell Carcinoma Head and Neck (SqCCHN), Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

411 Total Publications

Changing Role of Adjuvant Therapy in Stage III Melanoma.
Changing Role of Adjuvant Therapy in Stage III Melanoma.
Journal: The New England journal of medicine
Published: October 22, 2025
Similar Doctors
Irina Murakhovskaya
Elite in Autoimmune Hemolytic Anemia
Dr. Irina Murakhovskaya
Hematology
Elite in Autoimmune Hemolytic Anemia
Dr. Irina Murakhovskaya
Hematology

Montefiore Medical Park At Eastchester

1695 Eastchester Road, 
Bronx, NY 
 (8.0 miles away)
718-405-8505
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Irina Murakhovskaya is an Assistant Professor of Medicine (Hematology). She completed a medical degree at Albert Einstein College of Medicine and residency and fellowship training at Montefiore Health System. Her clinical interests focus on monoclonal gammopathy, low-grade lymphoma, and hematologic issues in pregnancy. Dr. Murakhovskaya is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Autoimmune Hemolytic Anemia, Thrombocytopenia, Adult Immune Thrombocytopenia, and Hemangioma Thrombocytopenia Syndrome.

Distinguished in Autoimmune Hemolytic Anemia
Dr. Bruce Raphael
Hematology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Bruce Raphael
Hematology

Office

240 E 38th St Fl 19, 
New York, NY 
 (1.8 miles away)
212-731-5540
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Raphael is a Hematologist in New York, New York. Dr. Raphael is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Essential Thrombocythemia, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration.

Distinguished in Autoimmune Hemolytic Anemia
Dr. Kenneth Hymes
Hematology
Distinguished in Autoimmune Hemolytic Anemia
Dr. Kenneth Hymes
Hematology

NYU Langone PCC BMT Center

610 2nd Ave, 
New York, NY 
 (1.8 miles away)
646-501-4848
Languages Spoken:
English
See accepted insurances

Kenneth Hymes is a Hematologist in New York, New York. Dr. Hymes is rated as a Distinguished provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Protein S Deficiency, Protein C Deficiency, Congenital Antithrombin 3 Deficiency, Hereditary Resistance to Anti-Vitamin K, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wolchok's expertise for a condition
ConditionClose
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile